Results 31 to 40 of about 577,308 (213)

Papel de la activación leucocitaria y plaquetaria en la trombosis de los síndromes mieloproliferativos crónicos [PDF]

, 2008
[spa] INTRODUCCIÓN Y OBJETIVOS: La causa fundamental de la trombosis en la policitemia vera y la trombocitemia esencial es el aumento de la viscosidad sanguínea secundaria a la eritrocitosis así como el incremento del número de plaquetas y las ...
Álvarez Larrán, Alberto
core   +4 more sources

Thrombotic incidents in patients with myelofibrosis suggest to be independent of JAK2 V617f mutational status [PDF]

Folia Medica, 2022
Introduction: Myelofibrosis (MF) belongs to a group of conditions known as Philadelphia-negative myeloproliferative neoplasms (MPN). Bleeding or various vascular complications could be the main causes of morbidity and mortality in patients with MF ...
Dragomira Nikolova, Atanas Radinov
doaj   +3 more sources

Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2 V617F Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study

Diagnostics, 2020
JAK2 V617F mutational status is an essential diagnostic index in myeloproliferative neoplasms (MPNs). Although widely used for detection of JAK2 V617F mutation in peripheral blood (PB), sensitive real-time quantitative PCR (qPCR) presents some ...
Francesco La Rocca, Vitina Grieco, Vitalba Ruggieri, Emanuela Zifarone, Oreste Villani, Pietro Zoppoli, Sabino Russi, Simona Laurino, Geppino Falco, Giovanni Calice, Anna Marinaccio, Maria Iole Natalicchio, Francesco Albano, Pellegrino Musto   +13 more
doaj   +1 more source

JAK2 V617F Mutation in Adult Taiwanese Patients with Essential Thrombocythemia: More Prevalent in Old Patients and Correlated with Higher Hemoglobin Level and Higher Leukocyte Count

International Journal of Gerontology, 2013
Background: Essential thrombocythemia (ET) is classified as a chronic myeloproliferative neoplasm. JAK2 V617F mutation is found in about 50–60% patients with ET. We aim to determine the prevalence of JAK2 V617F mutation and its association with phenotype
Huan-Chau Lin, Caleb Gon-Shen Chen, Ming-Chih Chang, Wei-Ting Wang, Chen Wei Kao, An-Chi Lo, Nai-Wen Su, Yu-Cheng Chang, Yi-Hao Chiang, Kuei-Fang Chou, Po-Nien Liao, Guan-Jhe Cai, Hung-I Cheng, Johnson Lin, Yi-Fang Chang, Ruey-Kuen Hsieh, Ken-Hong Lim   +16 more
doaj   +1 more source

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. [PDF]

PLoS ONE, 2006
A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the majority of patients with polycythemia vera (PV), and some with essential thrombocythemia (ET) and chronic idiopathic myelofibrosis.
Virginia M Zaleskas, Daniela S Krause, Katherine Lazarides, Nihal Patel, Yiguo Hu, Shaoguang Li, Richard A Van Etten   +6 more
doaj   +1 more source

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients

Journal of Biomedicine and Translational Research, 2015
Background : Three subtypes of myeloproliferative neoplasms (MPNs): Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) showed overlapping phenotype.
Fanti Saktini, Santosa Santosa, Sultana MH Faradz   +2 more
doaj   +1 more source

Somatic mutation of the V617F JAK2 gene in patients of the cardiovascular diseases

Терапевтический архив, 2019
The JAK2 V617F somatic mutation is one of the most frequent markers of CHIP (clonal hematopoiesis of indeterminate potential). CHIP is characterized by the presence of a myeloid cells clone in peripheral blood in the absence of the sufficient reasons to ...
I A Olkhovskiy, A S Gorbenko, M A Stolyar, D A Grischenko, O A Tkachenko, T L Martsinkevich   +5 more
doaj   +1 more source

Is the JAK2^V617F mutation detectable in healthy volunteers? [PDF]

American Journal of Hematology, 2010
The World Health Organization (WHO) has added detection of the JAK2 tyrosine kinase mutation, JAK2 V617F, in the diagnostic work up for myeloproliferative neoplasms (MPNs), especially for polycythemia vera (PV) and essential thrombocythemia (ET).
Christophe, Martinaud, Patrick, Brisou, Marie-Joelle, Mozziconacci   +2 more
openaire   +2 more sources

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia [PDF]

Leukemia, 2005
n ...
ANTONIOLI, ELISABETTA, GUGLIELMELLI, PAOLA, PANCRAZZI, ALESSANDRO, BOGANI, COSTANZA, Verrucci M, PONZIANI, VANESSA, Longo G, BOSI, ALBERTO, VANNUCCHI, ALESSANDRO MARIA   +8 more
openaire   +4 more sources

Abnormalities affecting tyrosine kinase signalling in atypical myeloproliferative disorders [PDF]

, 2009
The myeloproliferative disorders (MPDs) are a group of haematopoietic stem cell diseases, characterised by proliferation of one or more cells of the myeloid lineage.
Hidalgo-Curtis, Claire
core   +1 more source